The 2/29 PAX2 nonaberrant adenocarcinomas (PAX2 expressors) had been clinically tested for mismatch repair (MMR) deficiency by IHC; both retained expression of all 4 MMR markers. Here, PAX2 is linked to adenocarcinoma.